Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share
DNA.WS
DNA.WS was delisted on the 3rd of September, 2024.
35 hedge funds and large institutions have $1.99M invested in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 8 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
13% less funds holding
Funds holding: 40 → 35 (-5)
27% less capital invested
Capital invested by funds: $2.73M → $1.99M (-$737K)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Guggenheim Capital
Chicago,
Illinois
|
+$7.71M |
| 2 |
Walleye Capital
New York
|
+$197K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
+$101K |
| 4 |
Walleye Trading
New York
|
+$20.5K |
| 5 |
CAC
Cowen and Company
New York
|
+$13.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$85.3K |
| 2 |
ICM
Ionic Capital Management
New York
|
-$79.2K |
| 3 |
SS
Simplicity Solutions
Minneapolis,
Minnesota
|
-$28.7K |
| 4 |
VF
Virtu Financial
New York
|
-$4K |
| 5 |
Edgewood Management
Greenwich,
Connecticut
|
-$1.8K |
DNA.WS Hedge Fund Activity: Q2 2023 in Review
35 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) for Q2 2023, worth a combined $1.99M — down 27% from $2.73M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of DNA.WS and 3 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Guggenheim Capital, adding an estimated $7.71M. The largest seller was CVI Holdings, cutting an estimated $85.3K.
- 35 institutional investors held Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share (DNA.WS) as of Q2 2023, down from 40 in Q1 2023.
- Funds reported $1.99M of Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share stock for Q2 2023, down 27% quarter-over-quarter.
- 3 funds opened new Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share positions in Q2 2023 and 8 closed out, a net change of -5 holders.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share buyer in Q2 2023 was Guggenheim Capital, an estimated $7.71M added.
- The largest Ginkgo Bioworks Holdings, Inc. Warrants, each whole warrant exercisable to purchase one-fortieth (1/40th) of a share of Class A Common Stock at an exercise price of $460.00 per share seller in Q2 2023 was CVI Holdings, an estimated $85.3K sold.
Based on aggregated 13F filings for Q2 2023.